Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

After a heart attack, humans lose millions of heart muscle cells that cannot regrow, often leading to heart failure where the ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...

RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma (the "Company" or "RyCarma"), a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Researchers have discovered that the protein Hmga1, found in zebrafish, can repair damaged mouse hearts by reactivating ...

Researchers have successfully repaired damaged mouse hearts using a protein from zebrafish. They discovered that the protein Hmga1 plays a key role in heart regeneration in zebrafish. In mice, this ...

The data suggests that Hmga1, a key protein for regenerating heart cells, could be a target for gene therapies that prevent cardiac failure.

This study, supported by the Dutch Heart Foundation and Hartekind Foundation, marks an important step toward regenerative ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...